His scientific interests lie mostly in Internal medicine, Cardiology, Cholesterol, Myocardial infarction and Metabolic syndrome. His Internal medicine study frequently involves adjacent topics like Endocrinology. His Lipid lowering study in the realm of Endocrinology connects with subjects such as Losartan/hydrochlorothiazide.
His Cardiology research includes themes of Framingham Heart Study, Framingham Risk Score and Clinical trial. His Cholesterol research is multidisciplinary, relying on both National Health and Nutrition Examination Survey, Epidemiology, Gerontology and Public health. In his study, Apolipoprotein B is inextricably linked to Type 2 Diabetes Mellitus, which falls within the broad field of Metabolic syndrome.
His primary areas of study are Internal medicine, Surgery, Cardiology, Cholesterol and Myocardial infarction. His study explores the link between Internal medicine and topics such as Endocrinology that cross with problems in Primary prevention. His studies examine the connections between Cardiology and genetics, as well as such issues in Blood pressure, with regards to Physical therapy.
His work carried out in the field of Myocardial infarction brings together such families of science as Incidence and Pravastatin. His research in Lipoprotein intersects with topics in Diabetes mellitus and Triglyceride. His research integrates issues of Gerontology and National Cholesterol Education Program in his study of Clinical trial.
David J. Gordon mostly deals with Cancer research, Sarcoma, Ribonucleotide reductase, Cancer and Internal medicine. His studies in Cancer research integrate themes in fields like Cell culture, Cancer cell, Stem cell, DNA repair and Kinase. His Sarcoma research is multidisciplinary, incorporating perspectives in Carcinogenesis, In vitro and Virology.
His Ribonucleotide reductase research incorporates themes from DNA replication and Protein biosynthesis. His biological study deals with issues like Disease, which deal with fields such as Observational study. He has included themes like Oncology and Cardiology in his Internal medicine study.
David J. Gordon mainly investigates Internal medicine, Randomized controlled trial, Ribonucleotide reductase, Cancer research and Cancer. Many of his studies on Internal medicine apply to Vaccination as well. Randomized controlled trial is often connected to Clinical trial in his work.
David J. Gordon combines subjects such as Cancer cell, Sarcoma and Carcinogenesis with his study of Ribonucleotide reductase. His Cancer research study integrates concerns from other disciplines, such as HEK 293 cells and Immunology. His Disease research includes elements of Observational study, Stroke, Cholecalciferol, Vitamin D and neurology and Myocardial infarction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg;Jackson T. Wright;Barry R Davis;Jeffrey A. Cutler.
JAMA (2002)
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
D. J. Gordon;J. L. Probstfield;R. J. Garrison;Jim Neaton.
Circulation (1989)
Diagnosis and management of the metabolic syndrome
Scott M Grundy;James I. Cleeman;Stephen R. Daniels;Karen A. Donato.
Cardiology in Review (2005)
High-Density Lipoprotein — The Clinical Implications of Recent Studies
David J. Gordon;Basil M. Rifkind.
The New England Journal of Medicine (1989)
Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer The Women's Health Study: A Randomized Controlled Trial
I-Min Lee;Nancy R. Cook;J. Michael Gaziano;David Gordon.
JAMA (2005)
Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans
Gary J. Nabel;Elizabeth G. Nabel;Zhi Yong Yang;Bernard A. Fox.
Proceedings of the National Academy of Sciences of the United States of America (1993)
Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial
Nancy R. Cook;I-Min Lee;J. Michael Gaziano;David Gordon.
JAMA (2005)
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Manson Je;Cook Nr;Lee Im;Christen W.
The New England Journal of Medicine (2019)
Causes and consequences of aneuploidy in cancer
David J. Gordon;Benjamin Resio;David Pellman.
Nature Reviews Genetics (2012)
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
L A Turka;P S Linsley;H Lin;W Brady.
Proceedings of the National Academy of Sciences of the United States of America (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Brigham and Women's Hospital
ModeX Therapeutics
University of Chicago
University of Florida
University of Washington
Wake Forest University
Brigham and Women's Hospital
The University of Texas Health Science Center at Houston
Brigham and Women's Hospital
National Institutes of Health
University of Waterloo
University of Klagenfurt
International Food Policy Research Institute
Ludwig-Maximilians-Universität München
Florida International University
Konkuk University
University of Queensland
École Polytechnique Fédérale de Lausanne
University of Jaén
Spanish National Research Council
City University of New York
Max Planck Society
McGill University
Stony Brook University
University of Michigan–Ann Arbor
Cranfield University